Deep venous thrombosis (DVT) is one of the most common venous reflux disorders in vascular disease. On the basis of anticoagulant therapy, thrombolytic therapy is an active and effective option that has drawn a wide attention of international researchers and clinicians in the field. Therefore, it is of great significance to explore the best thrombolytic drug, dosage and thrombolytic mode, which not only can effectively remove thrombus but also can reduce bleeding. At present, urokinase and rt-PA are the most prevalent thrombolytic agents in the treatment of DVT worldwide, and most of the studies on the dosage and mode of such thrombolytic drugs conducted by various research groups and labs stay at empirical level. In this article, we make a comprehensive review concerning the current situation of thrombolysis rate, dosage, efficacy and safety of urokinase and rt-PA in clinical application for DVT on thrombolysis.